Analytical Data
-
Gene name
CD56
- Application
-
Alternative Names
CD56; NCAM1; MSK39; N-CAM-1; NCAM; Neural Cell Adhesion Molecule
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13591
-
Expression Region
Thr340~Val608
-
Molecular Weight
48-55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD56, also known as neural cell adhesion molecule (NCAM), is a cell surface glycoprotein primarily expressed on natural killer (NK) cells and certain neuronal populations. Its role in immune regulation, cell adhesion, and neuronal development has made it a significant focus of research. Studies have shown that CD56 is crucial for the activation, maturation, and function of NK cells, which are integral to the innate immune response against tumors and viral infections. Moreover, the dysregulation of CD56 expression is implicated in various immunological disorders and cancers, highlighting its potential as a biomarker for disease progression and treatment response. Recent advances in recombinant protein technology have enabled the production of CD56 fusion proteins, facilitating the exploration of its biochemical properties and interactions in vitro. Research is increasingly focused on understanding the structural characteristics of CD56, its signaling pathways, and how its interactions with other molecules influence immune responses. The development of CD56-targeted therapies is also under investigation, aiming to enhance NK cell activity against malignant cells. This multifaceted research effort underscores the importance of CD56 in both basic immunology and its translational potential in clinical applications, offering insights into novel therapeutic strategies for cancer and immune modulation.
